All Articles

Observations from American Cancer Society patient navigators on programs that have gained financial support for nonclinical lay patient navigation programs.

Immunotherapy drugs work by boosting the immune system so that a person’s own immune system works smarter to identify and destroy any cancer cells.

The medical management landscape for non–small cell lung cancer (NSCLC) has been changing with the rapidity of the seasons. Long gone is the day when all are treated equally.

Anyone, regardless of their pre-existing physical or mental health issues, can get cancer.

FDA Grants Priority Review to Application for Pembrolizumab Monotherapy as First-Line Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS ≥1%)

Researchers are chipping away at the genetic subtypes of non–small-cell lung cancer (NSCLC).

Entrectinib achieved high response rates as well as durable responses in patients with ROS1-positive non–small cell lung cancer (NSCLC), including patients with brain metastases, according to a pooled analysis of phase 1 and 2 trials.

Atezolizumab combined with carboplatin/etoposide represents a new standard of care for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), according to results from the phase 3 IMpower133 trial presented at the IASLC 19th World Conference on Lung Cancer.

Brigatinib significantly prolonged survival compared with crizotinib (standard of care) as first-line therapy in patients with advanced anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC).

The combination of nivolumab plus ipilimumab extended progression-free survival (PFS) versus stan­dard chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with a high tumor mutational burden (TMB).